ClinicalTrials.gg
RecruitingNCT06906016HBV-BiomarkUpdated Apr 2, 2025

New HBV Infection Biomarkers: Clinical Characterization and Impact on Management

An observational study in Chronic Hepatitis B Virus (HBV) Infection, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
900
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 53 studies in Hepatitis B, Chronic with a site in France — 7 open to participants now, 9 under way, none of them phase 3. Hepatitis B, Chronic · France.

Started
2023
with 1 other
Observational
9 of 53
3 open now
Registered
50th of 53
by date
Lead sponsor
2 of 53
Assistance Publique - Hôpitaux de Paris

Among the 53 studies in Hepatitis B, Chronic with a site in France, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 50th registered.

Hepatitis B, Chronic

898 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

7 of the 53 studies in Hepatitis B, Chronic with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Hepatitis B, Chronic with a site in France, or all of them as a file.
02

Study summary

Chronic Hepatitis B Virus (HBV) infection affects nearly 300 million people worldwide and is a leading cause of liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In France, it affects around 0.3% of the population. Current clinical practice relies on traditional biomarkers, such as HBV DNA and HBsAg, to monitor viral replication and disease progression. However, these biomarkers do not fully capture the viral activity or predict clinical outcomes. Recently, new biomarkers like HBcrAg and HBV RNA have emerged, showing promise for better understanding the natural history of the infection and guiding treatment decisions. The main objective of this research is to evaluate the predictive role of these biomarkers (HBcrAg, HBV RNA) in HBV-infected patients, focusing on their association with HBsAg seroconversion and their ability to predict clinical events like cirrhosis and HCC. Secondary objectives include describing the clinicobiological characteristics of patients, determining HBV genotypes, characterizing the impact of HBV on the host's transcriptome, and studying the biomarkers' role in different phases of the infection and treatment. The ultimate goal is to identify more accurate biomarkers to guide antiviral treatment, predict disease progression, and potentially determine when treatment can be safely discontinued.

Read the detailed description

This study focuses on the chronic Hepatitis B virus (HBV) infection, which affects nearly 300 million people globally, leading to cirrhosis, hepatocellular carcinoma (HCC), and other severe liver diseases. The objective is to evaluate new biomarkers for HBV infection, specifically HBV core-related antigen (HBcrAg) and HBV RNA, and their potential role in the clinical management and prognosis of the disease. Traditional biomarkers used to track viral replication and liver fibrosis, such as HBV DNA, HBeAg, and HBsAg, have limitations, which this study aims to address by exploring emerging biomarkers that could improve the understanding of the infection's natural history and response to antiviral treatments.

The population involved in the study includes patients diagnosed with chronic HBV infection and receiving care at Henri Mondor-Albert Chenevier University Hospital. Patients must be 18 years or older and have been infected with HBV (positive HBsAg for more than six months). Exclusion criteria include individuals with liver transplantation history, those unable to provide consent, pregnant or breastfeeding women, and those not affiliated with a Social Security scheme.

The study design includes both primary and secondary evaluation criteria. The primary criterion is the incidence of HBsAg seroconversion (absence of detectable HBsAg in serum). Secondary criteria include the proportion of patients positive for HBeAg, the incidence of clinical events like cirrhosis and HCC, and the molecular characterization of HBV, such as genotype distribution and the presence of co-infections like hepatitis C (HCV) or HIV. Other secondary criteria also include the measurement of liver fibrosis using Fibroscan and screening for HCC through abdominal ultrasound and alpha-fetoprotein (AFP) tests.

Research procedures involve routine medical consultations, with additional blood samples (9mL dry tube and 9mL Paxgene) collected for research purposes once a year. Patients will be followed for a period of 10 years, with regular monitoring of HBV biomarkers and liver status to evaluate the progression of the infection, the risk of developing liver disease, and the potential predictive value of new biomarkers for viral replication and clinical outcomes. The ultimate aim is to enhance HBV management by identifying predictive biomarkers and refining treatment strategies, particularly to optimize antiviral therapies and improve patient prognosis.

03

Conditions studied

  • Chronic Hepatitis B Virus (HBV) Infection

Keywords

  • Chronic Hepatitis B (HBV)
  • HBV RNA
  • HBV biomarkers
  • Hepatocellular carcinoma (HCC)
  • HBV genotyping
  • Hepatitis B treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients infected with HBV, followed in the hepatology department - Henri-Mondor University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old
  • Chronic infection (HbsAg positive carrier for more than 6 months)
  • Patient under care within the Henri Mondor-Albert Chenevier University Hospital group

Exclusion criteria

Exclusion Criteria:

  • History of liver transplantation for liver failure in the context of chronic infection
  • Protected adults, adults unable to express their consent
  • Pregnant or breastfeeding women
  • Person not affiliated with a Social Security system
  • Patient refusal to participate in the project
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
900 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort Study on Chronic HBV Infection

    This study is a cohort study. It follows a group of patients infected with HBV (Hepatitis B) over an extended period to evaluate the predictive role of biomarkers in the progression of the infection and the response to antiviral treatment. Patients are monitored over time, with regular sample collection to measure biomarkers and assess clinical and biological events, such as seroconversion or the emergence of complications like cirrhosis or liver cancer.

    Biological: Collection of blood samples for the study of HBV biomarkers

Interventions

  • BiologicalCollection of blood samples for the study of HBV biomarkers

    The intervention involves the additional and minimal collection of two blood samples during routine care procedures (9mL in a dry tube and 9mL in a Paxgene tube). These samples are specifically collected for research purposes and will be stored in the laboratory at the Henri Mondor Biobank Platform under the responsibility of Pr Bijan Ghaleh-Marzban for 15 years. The samples will be preserved under strict conditions and may be used for future analyses related to the pathology of HBV infection or other scientific advancements, with the patient's informed consent.

06

What researchers measure

Primary outcomes

  1. HBsAg Seroconversion Rate

    Defined by the absence of detectable AgHBs in the serum using ELISA test

    Time frame: 3 months

Secondary outcomes

  1. Incidence of Biological Events

    Monitoring the seroconversion of HBeAg using biological data, measured by the proportion of patients with HBeAg seroconversion.

    Time frame: 1 year

  2. Quantification of VHB Transcripts

    Quantitative analysis of VHB transcripts using PCR, measured in copies per milliliter (copies/ml).

    Time frame: 1 year

  3. Biomarker Quantification: VHB RNA

    Quantification of the virus biomarker VHB RNA during follow-up using PCR, measured in copies per milliliter (copies/ml).

    Time frame: 1 year

  4. Diagnosis of Liver Tumor

    Diagnostic assessment of liver tumors using medical imaging techniques, such as MRI

    Time frame: 1 year

  5. Incidence of Clinical Events

    Monitoring of clinical events, such as cirrhosis, measured by the proportion of patients affected by clinical events.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Clinical Research Unit (CRU) Henri Mondor.
    Creteil, Créteil 94000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2038, 179 months after the start.

Of 72 observational studies under Hepatitis B, Chronic, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 99. This study's planned 179 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2025
First posted
Apr 2, 2025
StartActual
Nov 28, 2023
Primary completionEst.
Nov 27, 2038
CompletionEst.
Nov 27, 2038
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06906016
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Nov 28, 2023
Primary completion
Nov 27, 2038 (estimated)
Completion
Nov 27, 2038 (estimated)
Last update
Apr 2, 2025

Study contacts

Vincent LEROY, Dr
Contact
vincent.leroy2@aphp.fr
+33 0149812325

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion